Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® ▼ (abemaciclib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Verzenios Summary of Product Characteristics (SmPC)
Is Verzenios® ▼ (abemaciclib) dose adjustment required for patients with hepatic impairment?
Abemaciclib dose adjustments are only required for patients with with severe hepatic impairment (Child-Pugh C). Decrease the dosing frequency to once daily in these patients.
UK_cFAQ_ABE013_Z2_HEPATIC_IMPAIRMENT
en-GB
Relative Potency and Half-Life of Abemaciclib increases in Patients with Severe Hepatic Impairment
No dose adjustments are necessary in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment.1
Abemaciclib is metabolised in the liver.
Mild (Child Pugh A) and moderate (Child Pugh B) hepatic impairment had no effect on the exposure of abemaciclib. In severe hepatic impairment (Child Pugh C), the potency adjusted unbound abemaciclib plus its active metabolites increased 2.4-fold. The half‑life of abemaciclib increased from 24 to 55 hours.1
References
1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: October 23, 2019
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays